Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-02-41
Phase 3
Completed
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Registration Number
- NCT00047528
- Lead Sponsor
- Alcon Research
- Brief Summary
To compare intraocular pressure lowering effectiveness of a combination drug vs. two individual drugs dosed alone.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie combination IOP lowering therapy in open-angle glaucoma?
How does combination therapy in NCT00047528 compare to standard-of-care monotherapies for ocular hypertension?
Which biomarkers correlate with response to combination IOP therapies in glaucoma patients?
What are the long-term adverse event profiles of combination IOP lowering drugs in phase 3 trials?
What alternative combination approaches or competitor drugs exist for managing open-angle glaucoma post-2003?
Trial Locations
- Locations (1)
Clinical Trial Sites
🇺🇸Fort Worth, Texas, United States
Clinical Trial Sites🇺🇸Fort Worth, Texas, United States